Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world big data study of apatinib in gastric cancer in Hubei Province
ChiCTR2000041317Phase 4Recruiting
- Sponsor
- Hubei Cancer Hospital
- Start
- Dec 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in gastric cancer (GC), sponsored by Hubei Cancer Hospital. Primary endpoint: Progression-free survival. Started Dec 2020; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2000041317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041317.